{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:06:53Z","timestamp":1790258813145,"version":"4.1.0"},"reference-count":115,"publisher":"Akademiai Kiado Zrt.","issue":"3","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["EUJMI"],"published-print":{"date-parts":[[2026,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lentinan, a\n                    <jats:italic>\u03b2<\/jats:italic>\n                    -(1,3)-glucan derived from the mushroom\n                    <jats:italic>Lentinus edodes<\/jats:italic>\n                    , is known for its health-beneficial including anti-oxidant, anti-inflammatory, and anti-tumor effects particularly in the gastrointestinal tract, and even regarded as adjuvant in cancer treatment in Asia. There is, however, a knowledge gap regarding lentinan's clinical application and the underlying mechanisms of its pleiotropic effects. This prompted us to perform a scoping review summarizing current knowledge of lentinan's\u00a0health-promoting and disease-alleviating properties in the gastrointestinal tract and beyond. Preclinical and clinical studies revealed protective and therapeutic effects of the compound in distinct gastrointestinal pathologies, including colitis, chemotherapy- and immunosuppression-induced intestinal injury, infection models as well as in colorectal carcinogenesis by modulating intestinal epithelial barrier integrity, immune signaling, and microbiota composition. Lentinan was reported to exert its anti-tumor effects by interfering with apoptosis, autophagy, stemness, and angiogenesis. Notably, lentinan enhanced the effectiveness of chemotherapy and chimeric antigen receptor T-cell (CAR-T) therapy, reduced treatment-related adverse events, improved survival and quality of life. The observed effects were dependent on lentinan's molecular weight, dose, and route of administration. In conclusion, lentinan application constitutes a promising intervention strategy in gastrointestinal and extra-intestinal including systemic morbidities that should be further investigated in preclinical and clinical studies.\n                  <\/jats:p>","DOI":"10.1556\/1886.2026.00023","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:39:12Z","timestamp":1779881952000},"page":"129-154","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic effects of Lentinan in gastrointestinal inflammation and carcinogenesis \u2013 A scoping review of evidence from preclinical and clinical studies"],"prefix":"10.1556","volume":"16","author":[{"given":"Jennifer S.","family":"Scholz","sequence":"first","affiliation":[{"name":"Institute of Microbiology, Infectious Diseases and Immunology, Gastrointestinal Microbiology Research Group, Charit\u00e9 - University Medicine Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bereswill","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Infectious Diseases and Immunology, Gastrointestinal Microbiology Research Group, Charit\u00e9 - University Medicine Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6399-651X","authenticated-orcid":true,"given":"Markus M.","family":"Heimesaat","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Infectious Diseases and Immunology, Gastrointestinal Microbiology Research Group, Charit\u00e9 - University Medicine Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"B1","series-title":"IJERPH","article-title":"Intestinal barrier in human health and disease","volume":"18","author":"Di Tommaso N","year":"2021","unstructured":"Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. IJERPH. 2021;18:12836."},{"key":"B2","series-title":"Exp Mol Med","first-page":"1","article-title":"Mechanisms regulating intestinal barrier integrity and its pathological implications","volume":"50","author":"Chelakkot C","year":"2018","unstructured":"Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:1\u20139."},{"key":"B3","series-title":"J Allergy Clin Immunol","first-page":"3","article-title":"Intestinal barrier function: molecular regulation and disease pathogenesis","volume":"124","author":"Groschwitz KR","year":"2009","unstructured":"Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3\u201320."},{"key":"B4","series-title":"Gastroenterology","first-page":"616","article-title":"Inflammation and the intestinal barrier: leukocyte\u2013Epithelial cell interactions, cell junction remodeling, and mucosal repair","volume":"151","author":"Luissint A-C","year":"2016","unstructured":"Luissint A-C, Parkos CA, Nusrat A. Inflammation and the intestinal barrier: leukocyte\u2013Epithelial cell interactions, cell junction remodeling, and mucosal repair. Gastroenterology. 2016;151:616\u201332."},{"key":"B5","series-title":"Annu Rev Immunol","first-page":"23","article-title":"Interaction between the Microbiota, Epithelia, and immune cells in the intestine","volume":"38","author":"Kayama H","year":"2020","unstructured":"Kayama H, Okumura R, Takeda K. Interaction between the Microbiota, Epithelia, and immune cells in the intestine. Annu Rev Immunol. 2020;38:23\u201348."},{"key":"B6","series-title":"Eur J Immunol","article-title":"Epithelial\u2010immune cell crosstalk for intestinal barrier homeostasis","volume":"54","author":"Yao Y","year":"2024","unstructured":"Yao Y, Shang W, Bao L, Peng Z, Wu C. Epithelial\u2010immune cell crosstalk for intestinal barrier homeostasis. Eur J Immunol. 2024;54:2350631."},{"key":"B7","series-title":"The Lancet Gastroenterol & Hepatol","first-page":"573","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath MF","year":"2025","unstructured":"Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. The Lancet Gastroenterol & Hepatol. 2025;10:573\u201392."},{"key":"B8","series-title":"Biomed & Pharmacother","article-title":"Review on the effect of chemotherapy on the intestinal barrier: epithelial permeability, mucus and bacterial translocation","volume":"162","author":"Dahlgren D","year":"2023","unstructured":"Dahlgren D, Lennern\u00e4s H. Review on the effect of chemotherapy on the intestinal barrier: epithelial permeability, mucus and bacterial translocation. Biomed & Pharmacother. 2023;162:114644."},{"key":"B9","series-title":"Infect Immun","first-page":"e00734","article-title":"Influenza virus infection impairs the gut's barrier properties and favors secondary enteric bacterial infection through reduced production of short-chain fatty acids","volume":"89","author":"Sencio V","year":"2021","unstructured":"Sencio V, Gallerand A, Gomes Machado M, Deruyter L, Heumel S, Soulard D, et\u00a0al. Influenza virus infection impairs the gut's barrier properties and favors secondary enteric bacterial infection through reduced production of short-chain fatty acids. Infect Immun. 2021;89:e00734\u201320."},{"key":"B10","series-title":"Crit Care","first-page":"279","article-title":"The digestive tract as the origin of systemic inflammation","volume":"20","author":"De Jong PR","year":"2016","unstructured":"De Jong PR, Gonz\u00e1lez-Navajas JM, Jansen NJG. The digestive tract as the origin of systemic inflammation. Crit Care. 2016;20:279."},{"key":"B11","series-title":"The Lancet Gastroenterol & Hepatol","first-page":"17","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"5","author":"Alatab S","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et\u00a0al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. The Lancet Gastroenterol & Hepatol. 2020;5:17\u201330."},{"key":"B12","series-title":"The Lancet","first-page":"2769","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et\u00a0al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769\u201378."},{"key":"B13","series-title":"Inflamm Bowel Dis","first-page":"742","article-title":"Quality of life in inflammatory bowel disease: a systematic review and Meta-analyses\u2014Part I","volume":"24","author":"Knowles SR","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and Meta-analyses\u2014Part I. Inflamm Bowel Dis. 2018;24:742\u201351."},{"key":"B14","series-title":"World J Gastroenterol","first-page":"6888","article-title":"Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease","volume":"28","author":"Xu Y-H","year":"2022","unstructured":"Xu Y-H, Zhu W-M, Guo Z. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol. 2022;28:6888\u201399."},{"key":"B15","series-title":"IJMS","first-page":"2789","article-title":"Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease","volume":"25","author":"Puca P","year":"2024","unstructured":"Puca P, Capobianco I, Coppola G, Di Vincenzo F, Trapani V, Petito V, et\u00a0al. Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease. IJMS. 2024;25:2789."},{"key":"B16","series-title":"Dig Liver Dis","first-page":"558","article-title":"From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: pathogenesis and impact of current therapies","volume":"53","author":"Fantini MC","year":"2021","unstructured":"Fantini MC, Guadagni I. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: pathogenesis and impact of current therapies. Dig Liver Dis. 2021;53:558\u201365."},{"key":"B17","series-title":"N Engl J Med","first-page":"1441","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie L","year":"2015","unstructured":"Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441\u201352."},{"key":"B18","series-title":"IJMS","first-page":"9498","article-title":"Integrating inflammatory and epigenetic signatures in IBD-Associated colorectal carcinogenesis: models, mechanisms, and clinical implications","volume":"26","author":"Triantaphyllopoulos KA","year":"2025","unstructured":"Triantaphyllopoulos KA, Ragia ND, Panagiotopoulou M-CE, Sourlingas TG. Integrating inflammatory and epigenetic signatures in IBD-Associated colorectal carcinogenesis: models, mechanisms, and clinical implications. IJMS. 2025;26:9498."},{"key":"B19","series-title":"IJMS","article-title":"The role of Gut Microbiota in colorectal cancer pathogenesis: a comprehensive literature review","volume":"26","author":"Paduraru DN","year":"2025","unstructured":"Paduraru DN, Palcau AC, Dinca VG, Ciuc DM, Constantinescu A. The role of Gut Microbiota in colorectal cancer pathogenesis: a comprehensive literature review. IJMS. 2025;26:11870."},{"key":"B20","series-title":"Cancer","article-title":"Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries","volume":"132","author":"Danpanichkul P","year":"2026","unstructured":"Danpanichkul P, Pang Y, Tothanarungroj P, Dejvajara D, Kim D, Saokhieo P, et\u00a0al. Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries. Cancer. 2026;132:e70245."},{"key":"B21","series-title":"Cancers","first-page":"4634","article-title":"Gastrointestinal tract cancers, an increasing burden of the modern era: epidemiology and prevention","volume":"15","author":"Kayali S","year":"2023","unstructured":"Kayali S, Marabotto E, Giannini E. Gastrointestinal tract cancers, an increasing burden of the modern era: epidemiology and prevention. Cancers. 2023;15:4634."},{"key":"B22","series-title":"Cancers","first-page":"48","article-title":"Gastric cancer: current status of diagnosis and treatment","volume":"5","author":"Takahashi T","year":"2013","unstructured":"Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers. 2013;5:48\u201363."},{"key":"B23","series-title":"Nat Rev Clin Oncol","first-page":"643","article-title":"Gastric cancer\u2014molecular and clinical dimensions","volume":"10","author":"Wadhwa R","year":"2013","unstructured":"Wadhwa R, Song S, Lee J-S, Yao Y, Wei Q, Ajani JA. Gastric cancer\u2014molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643\u201355."},{"key":"B24","series-title":"Gastric Cancer","first-page":"1263","article-title":"Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study","volume":"22","author":"Mokadem I","year":"2019","unstructured":"Mokadem I, Dijksterhuis WPM, Van Putten M, Heuthorst L, De Vos-Geelen JM, Haj MN, et\u00a0al. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 2019;22:1263\u201373."},{"key":"B25","series-title":"Int J Colorectal Dis","first-page":"10","article-title":"Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis","volume":"38","author":"Amonkar MM","year":"2023","unstructured":"Amonkar MM, Abderhalden LA, Frederickson AM, Aksomaityte A, Lang BM, Leconte P, et\u00a0al. Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis. Int J Colorectal Dis. 2023;38:10."},{"key":"B26","series-title":"Lancet","first-page":"294","article-title":"Colorectal cancer","volume":"404","author":"Eng C","year":"2024","unstructured":"Eng C, Yoshino T, Ru\u00edz-Garc\u00eda E, Mostafa N, Cann CG, O\u2019Brian B, et\u00a0al. Colorectal cancer. Lancet. 2024;404:294\u2013310."},{"key":"B27","series-title":"Gastric Cancer","first-page":"665","article-title":"Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences","volume":"25","author":"Rowsell A","year":"2022","unstructured":"Rowsell A, Sodergren SC, Vassiliou V, Darlington A-S, Guren MG, Alkhaffaf B, et\u00a0al. Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences. Gastric Cancer. 2022;25:665\u201377."},{"key":"B28","series-title":"JCM","first-page":"6211","article-title":"The quality of life of patients with surgically treated colorectal cancer: a narrative review","volume":"11","author":"\u015awi\u0105tkowski F","year":"2022","unstructured":"\u015awi\u0105tkowski F, G\u00f3rnicki T, Bu\u0142dy\u015b K, Chabowski M. The quality of life of patients with surgically treated colorectal cancer: a narrative review. JCM. 2022;11:6211."},{"key":"B29","series-title":"Nat Rev Clin Oncol","first-page":"429","article-title":"Gut microbiota in colorectal cancer development and therapy","volume":"20","author":"Wong CC","year":"2023","unstructured":"Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol 2023;20:429\u201352."},{"key":"B30","series-title":"Cell Biochem Biophys","first-page":"2637","article-title":"The gut microbiome and colorectal cancer: an integrative review of the underlying mechanisms","volume":"83","author":"Karam F","year":"2025","unstructured":"Karam F, El Deghel Y, Iratni R, Dakroub AH, Eid AH. The gut microbiome and colorectal cancer: an integrative review of the underlying mechanisms. Cell Biochem Biophys. 2025;83:2637\u201350."},{"key":"B31","series-title":"Adv Cancer Res","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali HI","year":"2022","unstructured":"Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022;155:131\u201366."},{"key":"B32","series-title":"Cancer","first-page":"228","article-title":"Chemotherapy\u2010induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford J","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy\u2010induced neutropenia: risks, consequences, and new directions for its management Cancer. 2004;100:228\u201337."},{"key":"B33","series-title":"Oncology (Williston Park)","first-page":"16","article-title":"Chemotherapy dose intensity and quality cancer care","volume":"20","author":"Lyman GH","year":"2006","unstructured":"Lyman GH. Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park). 2006;20:16\u201325."},{"key":"B34","series-title":"Eur J Pharmacol","first-page":"120","article-title":"The changes induced by cyclophosphamide in intestinal barrier and microflora in mice","volume":"714","author":"Yang J","year":"2013","unstructured":"Yang J, Liu K, Qu J, Wang X. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. Eur J Pharmacol. 2013;714:120\u201324."},{"key":"B35","series-title":"Pharmacol Res","article-title":"Modulation of intestinal barrier function by glucocorticoids: lessons from preclinical models","volume":"177","author":"Tena-Garitaonaindia M","year":"2022","unstructured":"Tena-Garitaonaindia M, Arredondo-Amador M, Mascaraque C, Asensio M, Marin JJG, Mart\u00ednez-Augustin O, et\u00a0al. Modulation of intestinal barrier function by glucocorticoids: lessons from preclinical models. Pharmacol Res. 2022;177:106056."},{"key":"B36","series-title":"Transplantation","first-page":"74","article-title":"Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and Gut Microbiota, and favors subsequent colonization by uropathogenic Escherichia coli","volume":"101","author":"Tourret J","year":"2017","unstructured":"Tourret J, Willing BP, Dion S, MacPherson J, Denamur E, Finlay BB. Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and Gut Microbiota, and favors subsequent colonization by uropathogenic Escherichia coli. Transplantation. 2017;101:74\u201382."},{"key":"B37","series-title":"Trends Cancer","first-page":"1058","article-title":"Clinical perspective and treatment of immune-related colitis after cancer immunotherapy","volume":"11","author":"Braun LM","year":"2025","unstructured":"Braun LM, Lu Y, Zeiser R. Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. Trends Cancer. 2025;11:1058\u201377."},{"key":"B38","series-title":"Immunological Rev","first-page":"11","article-title":"Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: current understanding and future directions","volume":"318","author":"Dougan M","year":"2023","unstructured":"Dougan M. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: current understanding and future directions. Immunological Rev. 2023;318:11\u201321."},{"key":"B39","series-title":"Front Pharmacol","article-title":"Chemotherapeutics-Induced intestinal mucositis: pathophysiology and potential treatment strategies","volume":"12","author":"Dahlgren D","year":"2021","unstructured":"Dahlgren D, Sj\u00f6blom M, Hellstr\u00f6m PM, Lennern\u00e4s H. Chemotherapeutics-Induced intestinal mucositis: pathophysiology and potential treatment strategies. Front Pharmacol. 2021;12:681417."},{"key":"B40","series-title":"Cell Metab","first-page":"1700","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg H","year":"2022","unstructured":"Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34:1700\u201318."},{"key":"B41","series-title":"Nat Rev Microbiol","first-page":"719","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu CL","year":"2023","unstructured":"Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21:719\u201333."},{"key":"B42","series-title":"IJMS","article-title":"Role of intestinal microbes in chronic liver diseases","volume":"23","author":"Xu M","year":"2022","unstructured":"Xu M, Luo K, Li J, Li Y, Zhang Y, Yuan Z, et\u00a0al. Role of intestinal microbes in chronic liver diseases. IJMS. 2022;23:12661."},{"key":"B43","series-title":"IJMS","first-page":"8351","article-title":"The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage","volume":"21","author":"Plaza-D\u00edaz J","year":"2020","unstructured":"Plaza-D\u00edaz J, Sol\u00eds-Urra P, Rodr\u00edguez-Rodr\u00edguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abad\u00eda-Molina F, et\u00a0al. The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage. IJMS. 2020;21:8351."},{"key":"B44","series-title":"Arch Med Res","article-title":"Implications of the liver-gut axis in liver disease: from mechanisms to therapeutic targets","volume":"56","author":"Ram\u00edrez-Mej\u00eda MM","year":"2025","unstructured":"Ram\u00edrez-Mej\u00eda MM, Ponciano-Rodr\u00edguez G, M\u00e9ndez-S\u00e1nchez N. Implications of the liver-gut axis in liver disease: from mechanisms to therapeutic targets. Arch Med Res. 2025;56:103335."},{"key":"B45","series-title":"Front Cell Infect Microbiol","article-title":"Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications","volume":"15","author":"Chang L","year":"2025","unstructured":"Chang L, Liu Y, Li H, Yan J, Wu W, Chen N, et\u00a0al. Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications. Front Cell Infect Microbiol. 2025;15:1717696."},{"key":"B46","series-title":"J Clin Invest","article-title":"Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations","volume":"135","author":"Schnabl B","year":"2025","unstructured":"Schnabl B, Damman CJ, Carr RM. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J Clin Invest. 2025;135:e186423."},{"key":"B47","series-title":"World J Gastroenterol","article-title":"Microbiome and gut-liver interactions: from mechanisms to therapies","volume":"31","author":"Anis MA","year":"2025","unstructured":"Anis MA, Shahid Y, Majeed AA, Abid S. Microbiome and gut-liver interactions: from mechanisms to therapies. World J Gastroenterol. 2025;31."},{"key":"B48","series-title":"Am J Physiology-Heart Circulatory Physiol","first-page":"H1227","article-title":"Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease","volume":"319","author":"Lewis CV","year":"2020","unstructured":"Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiology-Heart Circulatory Physiol. 2020;319:H1227\u201333."},{"key":"B49","series-title":"Hypertension","first-page":"1393","article-title":"Antihypertensives and antibiotics: impact on intestinal dysfunction and hypertension","volume":"80","author":"Lucas SE","year":"2023","unstructured":"Lucas SE, Walton SL, Mirabito Colafella KM, Mileto SJ, Lyras D, Denton KM. Antihypertensives and antibiotics: impact on intestinal dysfunction and hypertension. Hypertension. 2023;80:1393\u2013402."},{"key":"B50","series-title":"Clin Sci","first-page":"645","article-title":"The leaky gut and the gut microbiome in sepsis \u2013 targets in research and treatment","volume":"137","author":"Chancharoenthana W","year":"2023","unstructured":"Chancharoenthana W, Kamolratanakul S, Schultz MJ, Leelahavanichkul A. The leaky gut and the gut microbiome in sepsis \u2013 targets in research and treatment. Clin Sci. 2023;137:645\u201362."},{"key":"B51","series-title":"Trends Endocrinol & Metab","first-page":"247","article-title":"Gut barrier disruption and chronic disease","volume":"33","author":"Martel J","year":"2022","unstructured":"Martel J, Chang S-H, Ko Y-F, Hwang T-L, Young JD, Ojcius DM. Gut barrier disruption and chronic disease. Trends Endocrinol & Metab. 2022;33:247\u201365."},{"key":"B52","series-title":"CPB","first-page":"1835","article-title":"Recent insight into herbal bioactives-based novel approaches forChronic intestinal inflammatory disorders therapy","volume":"25","author":"Harwansh RK","year":"2024","unstructured":"Harwansh RK, Chauhan S, Deshmukh R, Mazumder R. Recent insight into herbal bioactives-based novel approaches forChronic intestinal inflammatory disorders therapy. CPB. 2024;25:1835\u201357."},{"key":"B53","series-title":"Front Pharmacol","article-title":"Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice","volume":"14","author":"Nisar A","year":"2023","unstructured":"Nisar A, Jagtap S, Vyavahare S, Deshpande M, Harsulkar A, Ranjekar P, et\u00a0al. Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice. Front Pharmacol. 2023;14:1177050."},{"key":"B54","series-title":"N Engl J Med","first-page":"1302","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart DC","year":"2021","unstructured":"Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med. 2021;385:1302\u201315."},{"key":"B55","series-title":"eBioMedicine","article-title":"From single-target to cellular niche targeting in Crohn\u2019s disease: intercepting bad communications","volume":"74","author":"Nayar S","year":"2021","unstructured":"Nayar S, Cho JH. From single-target to cellular niche targeting in Crohn\u2019s disease: intercepting bad communications. eBioMedicine. 2021;74:103690."},{"key":"B56","series-title":"Dig Dis","first-page":"5","article-title":"Anti-Cytokine strategies beyond anti-tumour necrosis Factor-\u03b1 therapy: pathophysiology and clinical implications","volume":"35","author":"Rogler G","year":"2017","unstructured":"Rogler G, Biedermann L, Scharl M. Anti-Cytokine strategies beyond anti-tumour necrosis Factor-\u03b1 therapy: pathophysiology and clinical implications. Dig Dis. 2017;35:5\u201312."},{"key":"B57","series-title":"Ann Allergy Asthma & Immunol","first-page":"718","article-title":"Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies","volume":"130","author":"Cannon L","year":"2023","unstructured":"Cannon L, Pan A, Kovalick L, Sarkissian A, Wu EY. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Ann Allergy Asthma & Immunol. 2023;130:718\u201326."},{"key":"B58","series-title":"Biomed Res Int","article-title":"Plants and plant\u2010derived molecules as natural immunomodulators","volume":"2023","author":"Zebeaman M","year":"2023","unstructured":"Zebeaman M, Tadesse MG, Bachheti RK, Bachheti A, Gebeyhu R, Chaubey KK. Plants and plant\u2010derived molecules as natural immunomodulators. Biomed Res Int. 2023;2023:7711297."},{"key":"B59","series-title":"Nutrients","first-page":"728","article-title":"Immunomodulatory effects of dietary polyphenols","volume":"13","author":"Shakoor H","year":"2021","unstructured":"Shakoor H, Feehan J, Apostolopoulos V, Platat C, Al Dhaheri AS, Ali HI, et\u00a0al. Immunomodulatory effects of dietary polyphenols. Nutrients. 2021;13:728."},{"key":"B60","series-title":"Sci Rep","first-page":"9539","article-title":"Forecasting of potential anti-inflammatory targets of some immunomodulatory plants and their constituents using in vitro, molecular docking and network pharmacology-based analysis","volume":"13","author":"Khairy A","year":"2023","unstructured":"Khairy A, Ghareeb DA, Celik I, Hammoda HM, Zaatout HH, Ibrahim RS. Forecasting of potential anti-inflammatory targets of some immunomodulatory plants and their constituents using in vitro, molecular docking and network pharmacology-based analysis. Sci Rep. 2023;13:9539."},{"key":"B61","series-title":"Nutrients","first-page":"4823","article-title":"Dietary Polyphenols\u2014natural bioactive compounds with potential for preventing and treating some allergic conditions","volume":"15","author":"D\u0119bi\u0144ska A","year":"2023","unstructured":"D\u0119bi\u0144ska A, Soza\u0144ska B. Dietary Polyphenols\u2014natural bioactive compounds with potential for preventing and treating some allergic conditions. Nutrients. 2023;15:4823."},{"key":"B62","series-title":"Food Funct","first-page":"3366","article-title":"Effects of fungal beta-glucans on health \u2013 a systematic review of randomized controlled trials","volume":"12","author":"Vlassopoulou M","year":"2021","unstructured":"Vlassopoulou M, Yannakoulia M, Pletsa V, Zervakis GI, Kyriacou A. Effects of fungal beta-glucans on health \u2013 a systematic review of randomized controlled trials. Food Funct. 2021;12:3366\u201380."},{"key":"B63","series-title":"Nutrients","first-page":"1333","article-title":"Immunomodulating effects of fungal beta-Glucans: from traditional use to medicine","volume":"13","author":"Van Steenwijk HP","year":"2021","unstructured":"Van Steenwijk HP, Bast A, De Boer A. Immunomodulating effects of fungal beta-Glucans: from traditional use to medicine. Nutrients. 2021;13:1333."},{"key":"B64","series-title":"Foods","first-page":"1009","article-title":"The mushroom glucans: molecules of high biological and medicinal importance","volume":"12","author":"Vetter J","year":"2023","unstructured":"Vetter J. The mushroom glucans: molecules of high biological and medicinal importance. Foods. 2023;12:1009."},{"key":"B65","series-title":"Progress in molecular biology and translational science","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/bs.pmbts.2019.02.013","article-title":"Mushroom polysaccharide lentinan for treating different types of cancers: a review of 12 years clinical studies in China","author":"Zhang M","year":"2019","unstructured":"Zhang M, Zhang Y, Zhang L, Tian Q. Mushroom polysaccharide lentinan for treating different types of cancers: a review of 12 years clinical studies in China. In: Progress in molecular biology and translational science. Elsevier; 2019. pp. 297\u2013328."},{"key":"B66","series-title":"Colloids Surf B: Biointerfaces","article-title":"Comprehensive mechanisms and advanced delivery strategies of lentinan in antitumor therapy: a review","volume":"258","author":"Zhen C","year":"2026","unstructured":"Zhen C, Guo J, Li R, Xiao H, Yang J, Wang L. Comprehensive mechanisms and advanced delivery strategies of lentinan in antitumor therapy: a review. Colloids Surf B: Biointerfaces. 2026;258:115228."},{"key":"B67","series-title":"Int J Food Sci Technology","article-title":"Fecal fermentation of lentinan and its effect on gut microbiota and metabolites","volume":"60","author":"Yang Y","year":"2025","unstructured":"Yang Y, Zhou X, Wang B, Wei L, Zhang Y, Wang X, et\u00a0al. Fecal fermentation of lentinan and its effect on gut microbiota and metabolites. Int J Food Sci Technology. 2025;60:vvae004."},{"key":"B68","series-title":"Intl J Cancer","first-page":"93","article-title":"Selective suppression of t\u2010cell activity in tumor\u2010bearing mice and its improvement by lentinan, a potent anti\u2010tumor polysaccharide","volume":"18","author":"Haba S","year":"1976","unstructured":"Haba S, Hamaoka T, Takatsu K, Kitagawa M. Selective suppression of t\u2010cell activity in tumor\u2010bearing mice and its improvement by lentinan, a potent anti\u2010tumor polysaccharide. Intl J Cancer. 1976;18:93\u2013104."},{"key":"B69","series-title":"Am J Physiology-Gastrointestinal Liver Physiol","first-page":"G712","article-title":"Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience","volume":"320","author":"Sougiannis AT","year":"2021","unstructured":"Sougiannis AT, VanderVeen BN, Davis JM, Fan D, Murphy EA. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiology-Gastrointestinal Liver Physiol. 2021;320:G712\u20139."},{"key":"B70","series-title":"Models in inflammation and immunopharmacology","first-page":"9","article-title":"Modeling gut barrier dysfunction and subsequent opportunistic infection by Candida albicans during chemotherapy-induced intestinal mucositis in mice","author":"Batista RRA","year":"2026","unstructured":"Batista RRA, Da Gra\u00e7a-Filho RV, Ozores GDN, De Lima AC, Fagundes CT. Modeling gut barrier dysfunction and subsequent opportunistic infection by Candida albicans during chemotherapy-induced intestinal mucositis in mice. In: Secchim Ribeiro L, editor. Models in inflammation and immunopharmacology. New York, NY: Springer US; 2026. pp. 9\u201328."},{"key":"B71","series-title":"The Lancet Respir Med","first-page":"623","article-title":"Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies","volume":"13","author":"Deinhardt-Emmer S","year":"2025","unstructured":"Deinhardt-Emmer S, Chousterman BG, Schefold JC, Floh\u00e9 SB, Skirecki T, Kox M, et\u00a0al. Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. The Lancet Respir Med. 2025;13:623\u201337."},{"key":"B72","series-title":"Carbohydr Polym","article-title":"Insights into oral lentinan immunomodulation: Dectin-1-mediated lymphatic transport from Peyer\u2019s patch M cells to mononuclear phagocytes","volume":"346","author":"Wang K","year":"2024","unstructured":"Wang K, Liu Y, Zhang Z, Zheng Z, Tang W, Teng W, et\u00a0al. Insights into oral lentinan immunomodulation: Dectin-1-mediated lymphatic transport from Peyer\u2019s patch M cells to mononuclear phagocytes. Carbohydr Polym. 2024;346:122586."},{"key":"B73","series-title":"J Agric Food Chem","first-page":"7344","article-title":"Mechanism of lentinan intestinal absorption: Clathrin-Mediated endocytosis and macropinocytosis","volume":"69","author":"Zheng Z","year":"2021","unstructured":"Zheng Z, Pan X, Wang H, Wu Z, Sullivan MA, Liu Y, et\u00a0al. Mechanism of lentinan intestinal absorption: Clathrin-Mediated endocytosis and macropinocytosis. J Agric Food Chem. 2021;69:7344\u201352."},{"key":"B74","series-title":"J Cell. Mol Medi","first-page":"750","article-title":"Therapeutic effects of lentinan on inflammatory bowel disease and colitis\u2010associated cancer","volume":"23","author":"Liu Y","year":"2019","unstructured":"Liu Y, Zhao J, Zhao Y, Zong S, Tian Y, Chen S, et\u00a0al. Therapeutic effects of lentinan on inflammatory bowel disease and colitis\u2010associated cancer. J Cell. Mol Medi. 2019;23:750\u201360."},{"key":"B75","series-title":"Mol Biotechnol","first-page":"2778","article-title":"Anti-inflammatory and anti-oxidant impacts of lentinan combined with probiotics in ulcerative colitis","volume":"66","author":"You C","year":"2024","unstructured":"You C, Xing J, Sun J, Zhang D, Yan Y, Dong Y. Anti-inflammatory and anti-oxidant impacts of lentinan combined with probiotics in ulcerative colitis. Mol Biotechnol. 2024;66:2778\u201391."},{"key":"B76","series-title":"Biosci Biotechnol Biochem","first-page":"2324","article-title":"Different suppressive effects of fucoidan and lentinan on IL-8 mRNA expression in in Vitro gut inflammation","volume":"73","author":"Mizuno M","year":"2009","unstructured":"Mizuno M, Nishitani Y, Hashimoto T, Kanazawa K. Different suppressive effects of fucoidan and lentinan on IL-8 mRNA expression in in Vitro gut inflammation. Biosci Biotechnol Biochem. 2009;73:2324\u20135."},{"key":"B77","series-title":"Int J Biol Macromolecules","article-title":"Lentinan mitigates ulcerative colitis via the IL-22 pathway to repair the compromised mucosal barrier and enhance antimicrobial defense","volume":"307","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Zhou Z, Zhang Z, Liu Y, Ji W, Wang J, et\u00a0al. Lentinan mitigates ulcerative colitis via the IL-22 pathway to repair the compromised mucosal barrier and enhance antimicrobial defense. Int J Biol Macromolecules. 2025;307:141784."},{"key":"B78","series-title":"Plos One","article-title":"Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells","volume":"8","author":"Nishitani Y","year":"2013","unstructured":"Nishitani Y, Zhang L, Yoshida M, Azuma T, Kanazawa K, Hashimoto T, et\u00a0al. Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. Plos One. 2013;8:e62441."},{"key":"B79","series-title":"Eur J Pharmacol","article-title":"The inhibitory effect of oral administration of lentinan on DSS-induced inflammation is exerted by the migration of T cells activated in the ileum to the colon","volume":"946","author":"Minato K","year":"2023","unstructured":"Minato K, Oura K, Mizuno M. The inhibitory effect of oral administration of lentinan on DSS-induced inflammation is exerted by the migration of T cells activated in the ileum to the colon. Eur J Pharmacol. 2023;946:175631."},{"key":"B80","series-title":"Food Funct","first-page":"479","article-title":"Lentinan modulates intestinal microbiota and enhances barrier integrity in a piglet model challenged with lipopolysaccharide","volume":"10","author":"Wang X","year":"2019","unstructured":"Wang X, Wang W, Wang L, Yu C, Zhang G, Zhu H, et\u00a0al. Lentinan modulates intestinal microbiota and enhances barrier integrity in a piglet model challenged with lipopolysaccharide. Food Funct. 2019;10:479\u201389."},{"key":"B81","series-title":"Int J Biol Macromolecules","first-page":"317","article-title":"Protective effects of lentinan on lipopolysaccharide induced inflammatory response in intestine of juvenile taimen (Hucho taimen, Pallas)","volume":"121","author":"Ren G","year":"2019","unstructured":"Ren G, Xu L, Lu T, Zhang Y, Wang Y, Yin J. Protective effects of lentinan on lipopolysaccharide induced inflammatory response in intestine of juvenile taimen (Hucho taimen, Pallas). Int J Biol Macromolecules. 2019;121:317\u201325."},{"key":"B82","series-title":"Carbohydr Polym","article-title":"Effect of the \u03b2-glucan from Lentinus edodes on colitis-associated colorectal cancer and gut microbiota","volume":"316","author":"Liu N","year":"2023","unstructured":"Liu N, Zou S, Xie C, Meng Y, Xu X. Effect of the \u03b2-glucan from Lentinus edodes on colitis-associated colorectal cancer and gut microbiota. Carbohydr Polym. 2023;316:121069."},{"key":"B83","series-title":"Oncotarget","first-page":"610","article-title":"A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice","volume":"8","author":"Wang J","year":"2017","unstructured":"Wang J, Li W, Huang X, Liu Y, Li Q, Zheng Z, et\u00a0al. A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice. Oncotarget. 2017;8:610\u201323."},{"key":"B84","series-title":"Front Pharmacol","article-title":"Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133\/p85\/p-AKT signaling axis","volume":"16","author":"Liu Y","year":"2025","unstructured":"Liu Y, Yang L, Liu J, He Z, Wang J, Zhang Y, et\u00a0al. Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133\/p85\/p-AKT signaling axis. Front Pharmacol. 2025;16:1725716."},{"key":"B85","series-title":"Carbohydr Polym","article-title":"Lentinan inhibited colon cancer growth by inducing endoplasmic reticulum stress-mediated autophagic cell death and apoptosis","volume":"267","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Liu Y, Zhou Y, Zheng Z, Tang W, Song M, et\u00a0al. Lentinan inhibited colon cancer growth by inducing endoplasmic reticulum stress-mediated autophagic cell death and apoptosis. Carbohydr Polym. 2021;267:118154."},{"key":"B86","series-title":"J Exp Clin Cancer Res","first-page":"260","article-title":"Lentinan inhibits tumor angiogenesis via interferon \u03b3 and in a T cell independent manner","volume":"37","author":"Deng S","year":"2018","unstructured":"Deng S, Zhang G, Kuai J, Fan P, Wang X, Zhou P, et\u00a0al. Lentinan inhibits tumor angiogenesis via interferon \u03b3 and in a T cell independent manner. J Exp Clin Cancer Res. 2018;37:260."},{"key":"B87","series-title":"Cancer Immunol Immunother","first-page":"120","article-title":"Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo","volume":"54","author":"Mushiake H","year":"2005","unstructured":"Mushiake H, Tsunoda T, Nukatsuka M, Shimao K, Fukushima M, Tahara H. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother. 2005;54:120\u20138."},{"key":"B88","series-title":"Front Immunol","article-title":"Lentinan enhances CAR-T cell potency in solid tumors by optimizing T cell differentiation","volume":"16","author":"Niu X","year":"2025","unstructured":"Niu X, Zhang P, Liu Z, Tang Y, Xu S, Wan X, et\u00a0al. Lentinan enhances CAR-T cell potency in solid tumors by optimizing T cell differentiation. Front Immunol. 2025;16:1605488."},{"key":"B89","series-title":"Int J Oncol","article-title":"Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells","volume":"36","author":"Liu","year":"2010","unstructured":"Liu. Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells. Int J Oncol. 2010;36."},{"key":"B90","series-title":"Tumor Biol","first-page":"1531","article-title":"Effect of lentinan combined with docetaxel and cisplatin on the proliferation and apoptosis of BGC823 cells","volume":"34","author":"Zhao L","year":"2013","unstructured":"Zhao L, Xiao Y, Xiao N. Effect of lentinan combined with docetaxel and cisplatin on the proliferation and apoptosis of BGC823 cells. Tumor Biol. 2013;34:1531\u20136."},{"key":"B91","series-title":"Eur J Cancer","first-page":"164","article-title":"Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701)","volume":"65","author":"Yoshino S","year":"2016","unstructured":"Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, et\u00a0al. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016;65:164\u201371."},{"key":"B92","series-title":"Anticancer Res","first-page":"2611","article-title":"Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer","volume":"29","author":"Hazama S","year":"2009","unstructured":"Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, et\u00a0al. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res. 2009;29:2611\u20137."},{"key":"B93","series-title":"Minerva Gastroenterol","first-page":"500","article-title":"Effect of lentinan injection combined with systemic chemotherapy on immune function and short-term efficacy of digestive tract malignant tumor","volume":"68","author":"Dong C","year":"2022","unstructured":"Dong C, Wang Y. Effect of lentinan injection combined with systemic chemotherapy on immune function and short-term efficacy of digestive tract malignant tumor. Minerva Gastroenterol. 2022;68:500\u20131."},{"key":"B94","series-title":"Med Sci","first-page":"8","article-title":"Chemo-Immunotherapy using lentinan for the treatment of gastric cancer with liver metastases","volume":"4","author":"Ina K","year":"2016","unstructured":"Ina K, Furuta R, Kataoka T, Kayukawa S, Ina H, Yoneda M. Chemo-Immunotherapy using lentinan for the treatment of gastric cancer with liver metastases. Med Sci. 2016;4:8."},{"key":"B95","series-title":"WJCO","first-page":"339","article-title":"Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy","volume":"2","author":"Ina K","year":"2011","unstructured":"Ina K. Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. WJCO. 2011;2:339."},{"key":"B96","series-title":"Anticancer Res","first-page":"2365","article-title":"The effect of lentinan combination therapy for unresectable advanced gastric cancer","volume":"32","author":"Higashi D","year":"2012","unstructured":"Higashi D, Seki K, Ishibashi Y, Egawa Y, Koga M, Sasaki T, et\u00a0al. The effect of lentinan combination therapy for unresectable advanced gastric cancer. Anticancer Res. 2012;32:2365\u20138."},{"key":"B97","series-title":"Hepatogastroenterology","first-page":"547","article-title":"Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life","volume":"56","author":"Kataoka H","year":"2009","unstructured":"Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et\u00a0al. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepatogastroenterology. 2009;56:547\u201350."},{"key":"B98","series-title":"Hepatogastroenterology","first-page":"172","article-title":"Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer","volume":"57","author":"Yoshino S","year":"2010","unstructured":"Yoshino S, Watanabe S, Imano M, Suga T, Nakazawa S, Hazama S, et\u00a0al. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer. Hepatogastroenterology. 2010;57:172\u20137."},{"issue":"3","key":"B99","series-title":"Mol Med Rep","first-page":"745","article-title":"Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma","volume":"5","author":"Wang JL","year":"2012","unstructured":"Wang JL, Bi Z, Zou JW, Gu XM. Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Mol Med Rep. 2012;5(3):745\u20138."},{"key":"B100","series-title":"AMB Expr","first-page":"11","article-title":"Lentinan's effect on gut microbiota and inflammatory cytokines in 5-FU-induced mucositis mice","volume":"15","author":"Zhang X","year":"2025","unstructured":"Zhang X, Wang L, Khan AI, Rehman AU, Khinsar KH, Xin Y. Lentinan's effect on gut microbiota and inflammatory cytokines in 5-FU-induced mucositis mice. AMB Expr. 2025;15:11."},{"key":"B101","series-title":"Int Immunopharmacology","first-page":"55","article-title":"Lentinan diminishes apoptotic bodies in the ileal crypts associated with S-1 administration","volume":"50","author":"Suga Y","year":"2017","unstructured":"Suga Y, Takehana K. Lentinan diminishes apoptotic bodies in the ileal crypts associated with S-1 administration. Int Immunopharmacology. 2017;50:55\u201360."},{"key":"B102","series-title":"Sci Rep","article-title":"Lentinan improves intestinal inflammation and gut dysbiosis in antibiotics-induced mice","volume":"12","author":"Ji X","year":"2022","unstructured":"Ji X, Su L, Zhang P, Yue Q, Zhao C, Sun X, et\u00a0al. Lentinan improves intestinal inflammation and gut dysbiosis in antibiotics-induced mice. Sci Rep. 2022;12:19609."},{"key":"B103","series-title":"Front Immunol","article-title":"Lentinan -triggered butyrate-producing bacteria drive the expulsion of the intestinal helminth Trichinella spiralis in mice","volume":"13","author":"Jin X","year":"2022","unstructured":"Jin X, Liu Y, Vallee I, Karadjian G, Liu M, Liu X. Lentinan -triggered butyrate-producing bacteria drive the expulsion of the intestinal helminth Trichinella spiralis in mice. Front Immunol. 2022;13:926765."},{"key":"B104","series-title":"J Anim Sci Biotechnol","first-page":"43","article-title":"Lentinan administration alleviates diarrhea of rotavirus-infected weaned pigs via regulating intestinal immunity","volume":"12","author":"Fan X","year":"2021","unstructured":"Fan X, Hu H, Chen D, Yu B, He J, Yu J, et\u00a0al. Lentinan administration alleviates diarrhea of rotavirus-infected weaned pigs via regulating intestinal immunity. J Anim Sci Biotechnol. 2021;12:43."},{"key":"B105","series-title":"Food Funct","first-page":"2094","article-title":"Lentinan administration relieves gut barrier dysfunction induced by rotavirus in a weaned piglet model","volume":"10","author":"Mao X","year":"2019","unstructured":"Mao X, Hu H, Xiao X, Chen D, Yu B, He J, et\u00a0al. Lentinan administration relieves gut barrier dysfunction induced by rotavirus in a weaned piglet model. Food Funct. 2019;10:2094\u2013101."},{"key":"B106","series-title":"Front Immunol","article-title":"Supplementation of dietary crude lentinan improves the intestinal microbiota and immune barrier in rainbow trout (Oncorhynchus mykiss) infected by infectious hematopoietic necrosis virus","volume":"13","author":"Ren G","year":"2022","unstructured":"Ren G, Xu L, Zhao J, Shao Y, Chen X, Lu T, et\u00a0al. Supplementation of dietary crude lentinan improves the intestinal microbiota and immune barrier in rainbow trout (Oncorhynchus mykiss) infected by infectious hematopoietic necrosis virus. Front Immunol. 2022;13:920065."},{"key":"B107","series-title":"IJMS","article-title":"Extraction and identification of polysaccharide from Lentinus edodes and its effect on immunosuppression and intestinal barrier injury induced by cyclophosphamide","volume":"25","author":"Jin X","year":"2024","unstructured":"Jin X, Wu Z, Chen H, Liu W, Gu F, Li J. Extraction and identification of polysaccharide from Lentinus edodes and its effect on immunosuppression and intestinal barrier injury induced by cyclophosphamide. IJMS. 2024;25:12432."},{"key":"B108","series-title":"Int J Biol Macromolecules","first-page":"169","article-title":"Effect of Lentinan on Peyer's patch structure and function in an immunosuppressed mouse model","volume":"137","author":"Jiang Y","year":"2019","unstructured":"Jiang Y, Li X, Wu Y, Zhou L, Wang Z, Xiao W. Effect of Lentinan on Peyer's patch structure and function in an immunosuppressed mouse model. Int J Biol Macromolecules. 2019;137:169\u201376."},{"key":"B109","series-title":"Int J Biol Macromolecules","article-title":"The effect of lentinan on dexamethasone-induced immunosuppression in mice","volume":"264","author":"Jiao L","year":"2024","unstructured":"Jiao L, Jin H, Song Z, Wang Z, Yu L, Yu R, et\u00a0al. The effect of lentinan on dexamethasone-induced immunosuppression in mice. Int J Biol Macromolecules. 2024;264:130621."},{"key":"B110","series-title":"J Immunol Res","first-page":"1","article-title":"Lentinan Attenuates damage of the small intestinal Mucosa, liver, and lung in mice with gut-origin Sepsis","author":"Kuang Z","year":"2021","unstructured":"Kuang Z, Jin T, Wu C, Zong Y, Yin P, Dong W, et\u00a0al. Lentinan Attenuates damage of the small intestinal Mucosa, liver, and lung in mice with gut-origin Sepsis. J Immunol Res. 2021; 2021:1\u201311."},{"key":"B111","series-title":"Int Immunopharmacology","article-title":"Lentinan ameliorates angiotensin II-induced hypertension-associated intestinal barrier injury through inactivation of PSMB8-ATRAP signaling","volume":"164","author":"Zhao D","year":"2025","unstructured":"Zhao D, Cai Y, Chen B, Pan Y, Chen D, Xie J, et\u00a0al. Lentinan ameliorates angiotensin II-induced hypertension-associated intestinal barrier injury through inactivation of PSMB8-ATRAP signaling. Int Immunopharmacology. 2025;164:115418."},{"key":"B112","series-title":"Front Nutr","article-title":"Lentinan supplementation protects the gut\u2013liver axis and prevents steatohepatitis: the role of gut Microbiota involved","volume":"8","author":"Yang X","year":"2022","unstructured":"Yang X, Zheng M, Zhou M, Zhou L, Ge X, Pang N, et\u00a0al. Lentinan supplementation protects the gut\u2013liver axis and prevents steatohepatitis: the role of gut Microbiota involved. Front Nutr. 2022;8:803691."},{"key":"B113","series-title":"Food Funct","first-page":"10067","article-title":"The dose-dependent mechanism behind the protective effect of lentinan against acute alcoholic liver injury via proliferating intestinal probiotics","volume":"15","author":"Zhao F","year":"2024","unstructured":"Zhao F, Li M, Luo M, Zhang M, Yuan Y, Niu H, et\u00a0al. The dose-dependent mechanism behind the protective effect of lentinan against acute alcoholic liver injury via proliferating intestinal probiotics. Food Funct. 2024;15:10067\u201387."},{"key":"B114","series-title":"Int J Biol Macromolecules","article-title":"Lentinan enhances microbiota-derived isoursodeoxycholic acid levels to alleviate hepatic ischemia-reperfusion injury in mice","volume":"304","author":"Li J","year":"2025","unstructured":"Li J, Bao J, Liu Y, Chen M, Chen Y, Tuolihong L, et\u00a0al. Lentinan enhances microbiota-derived isoursodeoxycholic acid levels to alleviate hepatic ischemia-reperfusion injury in mice. Int J Biol Macromolecules. 2025;304:140717."},{"key":"B115","series-title":"Eur J Cancer","first-page":"164","article-title":"Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701)","volume":"65","author":"Yoshino S","year":"2016","unstructured":"Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, et\u00a0al. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016;65:164\u201371."}],"container-title":["European Journal of Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/1886\/16\/3\/article-p129.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/1886\/16\/3\/article-p129.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/1886\/16\/3\/article-p129.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:48:48Z","timestamp":1790257728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/1886\/16\/3\/article-p129.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":115,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/1886.2026.00023","relation":{},"ISSN":["2062-509X","2062-8633"],"issn-type":[{"value":"2062-509X","type":"print"},{"value":"2062-8633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}